AbbVie Inc has joined the competition amongst large pharma companies for leadership of the market for antibody-drug conjugates (ADCs) with the proposed acquisition of ImmunoGen Inc of Waltham, Massachusetts for $31.26 per share in cash or an enterprise value of $10.1 billion. The acquisition was announced on 30 November and is expected to complete in the middle of 2024.
